An observational study in Acute Exacerbation of COPD, Acute Exacerbation of Bronchiectasis and Acute Exacerbation of Asthma, sponsored by Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-18.
Sponsored by Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil · Observational
Among 90 studies in Lung Diseases, Interstitial with a site in France — 37 open to participants now, 48 under way, 15 of them phase 3. Lung Diseases, Interstitial · France.
Among the 90 studies in Lung Diseases, Interstitial with a site in France, this one is the 27th largest by planned enrollment of the 30 observational ones, is one of 5 that started in 2019, is one of 30 observational ones, and was the 23rd registered.
680 studies on the registry are indexed under Lung Diseases, Interstitial; 246 are open to participants now.
This study's planned enrollment of 40 is below the median of 157 across 278 observational studies indexed under Lung Diseases, Interstitial.
Browse Lung Diseases, Interstitial studies →37 of the 90 studies in Lung Diseases, Interstitial with a site in France are open now, in 12 countries. Each count lists the studies.
Of the 174 Lung Diseases, Interstitial studies recruiting now, 109 (63%) set no upper age limit and 26 (15%) stop at 75 or younger; 13 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →90 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2019.
Median enrollment 138 across the 60 interventional studies, 265 across the 30 observational. Of the 34 that completed or were terminated, 12 (35%) have results posted.
36 of 90 have an industry lead sponsor. The 10 most frequent:
Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil is the lead sponsor of 22 studies on the registry; 1 is open to participants now.
Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil has 1 study filed under Lung Diseases, Interstitial — fewer than ten, so there is no comparison to draw.
15 of the studies in Lung Diseases, Interstitial with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06806592Phase 3Boehringer IngelheimA Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases | 2027-04-15 |
| NCT05943535Phase 3United TherapeuticsStudy of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | 2027-11 |
| NCT06235645University Hospital, ToursdEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasound | 2026-11 |
| NCT06892951University Hospital, ToursCaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia | 2026-12 |
Among the 90 studies in Lung Diseases, Interstitial with a site in France, from their registry updates:
Observational study in patients with chronic respiratory diseases (chronic obstructive pulmonary diseases, bronchiectasis, interstitial lung diseases, neuromuscular diseases, obesity-hypoventilation syndrome...) admitted in intensive care unit for acute respiratory failure. The main objective is to determine the prevalence of right ventricular (RV) dysfunction in this population and to analyze the impact of such a complication on outcomes (survival at day-28, duration of non-invasive or mechanical ventilation, duration of hospital stay). RV function will be assessed by echocardiography at admission, after 3 days and at discharge. Plasma NT-proBNP and troponin levels will be collected.
Observational study in patients with chronic respiratory diseases (chronic obstructive pulmonary diseases, bronchiectasis, interstitial lung diseases, neuromuscular diseases, obesity-hypoventilation syndrome...) admitted in intensive care unit for acute respiratory failure.
Inclusion Criteria:
Exclusion Criteria:
Observational study in patients with chronic respiratory diseases (chronic obstructive pulmonary diseases, bronchiectasis, interstitial lung diseases, neuromuscular diseases, obesity-hypoventilation syndrome...) admitted in intensive care unit for acute respiratory failure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Survival
Survival at day 28
Time frame: Day 28
Duration of ventilation
Duration of non-invasive ventilation and/or mechanical ventilation
Time frame: Day 28
Duration of hospital stay
Duration of hospital stay
Time frame: Day 28
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2019 (actual). Primary completion is estimated for Oct 2022, 37 months after the start.
Of 111 non-industry observational studies under Lung Diseases, Interstitial, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 274. This study's planned 37 months is below that.
Counting every sponsor, half of 132 studies reached it within 55 months; a quarter within 31 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil